- Home
- DMLP vs VRDN Comparison
DMLP vs VRDN Comparison
Compare DMLP & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- VRDN
- Stock Information
- Founded
- DMLP 2003
- VRDN 2006
- Country
- DMLP United States
- VRDN United States
- Employees
- DMLP N/A
- VRDN N/A
- Industry
- DMLP Oil & Gas Production
- VRDN Medical Specialities
- Sector
- DMLP Energy
- VRDN Health Care
- Exchange
- DMLP Nasdaq
- VRDN Nasdaq
- Market Cap
- DMLP 1.3B
- VRDN 1.3B
- IPO Year
- DMLP N/A
- VRDN N/A
- Fundamental
- Price
- DMLP $27.52
- VRDN $17.28
- Analyst Decision
- DMLP
- VRDN Strong Buy
- Analyst Count
- DMLP 0
- VRDN 11
- Target Price
- DMLP N/A
- VRDN $38.50
- AVG Volume (30 Days)
- DMLP 65.1K
- VRDN 667.1K
- Earning Date
- DMLP 08-08-2025
- VRDN 08-07-2025
- Dividend Yield
- DMLP 11.75%
- VRDN N/A
- EPS Growth
- DMLP N/A
- VRDN N/A
- EPS
- DMLP 2.03
- VRDN N/A
- Revenue
- DMLP $166,824,000.00
- VRDN $302,000.00
- Revenue This Year
- DMLP N/A
- VRDN N/A
- Revenue Next Year
- DMLP N/A
- VRDN $17,102.33
- P/E Ratio
- DMLP $13.56
- VRDN N/A
- Revenue Growth
- DMLP 12.09
- VRDN 4.86
- 52 Week Low
- DMLP $25.84
- VRDN $9.90
- 52 Week High
- DMLP $34.88
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- DMLP 49.03
- VRDN 60.64
- Support Level
- DMLP $27.10
- VRDN $16.46
- Resistance Level
- DMLP $27.89
- VRDN $18.44
- Average True Range (ATR)
- DMLP 0.40
- VRDN 0.81
- MACD
- DMLP -0.00
- VRDN 0.04
- Stochastic Oscillator
- DMLP 46.67
- VRDN 57.82
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).